BridgeMD
New treatment option for Alzheimer's Disease
Official title Transcranial Photobiomodulation (tPBM) in Alzheimer's Disease Study
ClinicalTrials.gov ID: NCT07224607
What this study is testing
- What it's testing
- The purpose of this study is to see if a special light treatment, called photobiomodulation, can help people with memory problems such as Mild Cognitive Impairment or Mild Dementia due to Alzheimer's disease. The light is given to the forehead using an FDA-cleared medical device.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 55 to 89
You may be able to join if
- Signed and dated informed consent form (either by subject or LAR)
- Willingness and ability to comply with all study procedures
- Age 55 to 89 years, inclusive
- Clinical diagnosis of Mild Cognitive Impairment or mild dementia (CDR Global = 0-1; MoCA 16-25) due to probable Alzheimer's disease diagnosis
- Ability to attend in-person sessions at Cedars-Sinai and adhere to weekly visits
You likely can't join if
- Presence of significant neurological conditions other than AD (e.g., epilepsy, Parkinson, etc.)
- History of Seizures
- If patient holds neuroimaging showing space-occupying lesions
- If patient holds imaging with Fazekas greater than or equal to 3, more than 2 lacunar infarcts, and/or more than 5 microhemorrhages
- Current pregnancy or lactation (although unlikely in this population)
- Participation in another clinical trial or investigational drug within the past 30 days
See the full eligibility criteria
- Signed and dated informed consent form (either by subject or LAR)
- Willingness and ability to comply with all study procedures
- Age 55 to 89 years, inclusive
- Clinical diagnosis of Mild Cognitive Impairment or mild dementia (CDR Global = 0-1; MoCA 16-25) due to probable Alzheimer's disease diagnosis
- Ability to attend in-person sessions at Cedars-Sinai and adhere to weekly visits
- Stable dose of Alzheimer's disease medications (e.g., donepezil, rivastigmine, memantine, galantamine) for at least 4 weeks prior to enrollment, if applicable
- Presence of significant neurological conditions other than AD (e.g., epilepsy, Parkinson, etc.)
- History of Seizures
- If patient holds neuroimaging showing space-occupying lesions
- If patient holds imaging with Fazekas greater than or equal to 3, more than 2 lacunar infarcts, and/or more than 5 microhemorrhages
- Current pregnancy or lactation (although unlikely in this population)
- Participation in another clinical trial or investigational drug within the past 30 days
- Active use of illicit substances or non-prescribed psychoactive drugs within the past 30 days.
- Severe dementia due to Alzheimer's disease or another etiology
- Physical or mental impairment that prevents the participant from complying with the cognitive testing battery.
The study team makes the final eligibility decision.
Where it's taking place
- Los Angeles, California, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 55 years to 89 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Los Angeles, California, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.